DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom (NASDAQ:DXCM) management will present a company update at the Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation is scheduled to begin at approximately 2:00 PM GMT (9:00 AM EST) and will be webcast live. Webcast links and an archived recording will be available at investors.dexcom.com.
Dexcom (DXCM) launched A Letter to Diabetes, a global campaign inviting people affected by diabetes to share their personal experiences. Throughout November, people living with diabetes, caregivers, loved ones and healthcare professionals can submit letters at ALetterToDiabetes.com. The campaign marks National Diabetes Awareness Month and World Diabetes Day and features stories from participants including Nick Jonas.
Dexcom (Nasdaq: DXCM) reported third-quarter 2026 revenue growth of 11% year over year alongside higher operating income and diluted earnings per share. Revenue reached $1,344.5 million. GAAP operating income rose to $327.2 million from $242.5 million, with operating margin increasing to 24.3% from 20.1%. GAAP net income fell to $275.1 million from $283.8 million, while diluted earnings per share increased to $0.72 from $0.70.
Dexcom raised its full-year revenue guidance midpoint, targeting $5.20–$5.25 billion, and increased its adjusted operating margin outlook to approximately 24%. It authorized share repurchases of up to $1.0 billion. Cash, cash equivalents and marketable securities totaled $1.82 billion at September 30. Dexcom also secured its first two international regulatory clearances for G7 15 Day and published the CONNECT randomized clinical trial after quarter-end.
Dexcom (NASDAQ: DXCM) will launch its G7 15 Day continuous glucose monitoring system in Canada in November for adults with diabetes.
The Health Canada-authorized system is intended for people 18 years and older and offers up to 15.5 days of wear. Public reimbursement will begin in November for many eligible Canadians with type 1 and type 2 diabetes. Private health plans that cover continuous glucose monitors will also begin adding coverage that month. Dexcom is working with automated insulin delivery partners to finalize integration and expects to extend the launch to their customers shortly.
Dexcom (NASDAQ: DXCM) announced publication of its CONNECT randomized trial evaluating Dexcom G7 in adults with Type 2 diabetes not using insulin.
The study appeared in The New England Journal of Medicine. G7 users had an average 1.6% A1C reduction from a mean baseline of 8.8%, exceeding routine care's reduction by 0.9%. A1C measures longer-term blood sugar levels. Users spent approximately five additional hours daily in the 70–180 mg/dL glucose target range versus routine care. At 26 weeks, 68% of G7 users achieved A1C below 7.5%, and 46% achieved below 7.0%; 97% of participants were still using CGM, most daily. Among participants using GLP-1 therapies, continuous glucose monitoring produced an additional 0.9% A1C reduction versus routine care. Benefits were observed across demographic characteristics and glucose-lowering medications.
Dexcom (NASDAQ:DXCM) plans to release its third quarter 2026 financial results after market close on October 29, 2026.
Management will review the quarter’s performance on a conference call at 4:30 p.m. Eastern Time that day. A concurrent webcast will be available on the company’s investor relations website and archived for future reference.
Dexcom (DXCM) launched the fifth season of Dexcom U, its name, image and likeness program for college athletes with diabetes. The 2026–2027 roster includes 27 athletes across 13 sports, with 12 new and 15 returning participants, its largest roster to date. Dexcom plans to host Dexcom U Days this fall at selected athletes’ games, connecting young athletes with diabetes with collegiate participants.
A Dexcom survey found that young adults with Type 1 diabetes quitting sports after diagnosis fell from 24% in 2022 to 16% in 2026, while sports participation rose from 81% to 85%. Among respondents who quit sports, 62% feared low glucose levels and 54% found diabetes management during activity too complicated, up from 42%. The online survey included 1,004 U.S. adults with Type 1 diabetes or parents of children with the condition.
Dexcom (DXCM) released a global Type 2 diabetes survey report and announced a monitoring partnership with Team Novo Nordisk.
Based on surveys of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries, the report found that 89% of professionals believe continuous glucose monitoring (CGM) helps assess treatment adherence between visits. Among people with Type 2 diabetes, 55% reported limited CGM knowledge. Coverage and reimbursement barriers were cited by 90% of U.S. professionals and 53% in the other seven countries. Among current CGM users, 94% reported managing diabetes more independently, and 93% found CGM easy to use.
58% of Type 2 GLP-1 users pair CGM with their medication, while 27% of Type 2 non-insulin users do so. Dexcom will become the cycling team’s official CGM partner. The partnership is intended to support real-world research, education and awareness for people with Type 1 diabetes.
Dexcom (DXCM) has promoted Executive Vice President and Chief Financial Officer Jereme Sylvain to the additional role of Chief Operating Officer.
In this expanded position, Sylvain will oversee Dexcom’s global operations and quality teams to support the company’s growth vision and focus on operational excellence. He joined Dexcom in 2018 and has served as CFO since 2021, during which time he built a finance leadership team and helped guide growth and margin expansion. Dexcom’s CEO, Jake Leach, described Sylvain as an exceptional leader whose strategic judgment, operational discipline, and customer focus align with the company’s next phase of growth.
Dexcom (DXCM) has appointed Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein is a veteran healthcare and finance executive with over 20 years of medical technology experience, most recently serving as Vice President and Chief Financial Officer of Stryker Corporation. He brings expertise in financial leadership, capital allocation, strategic M&A, and operations to support Dexcom’s long-range growth plans in diabetes and metabolic health.